Volition Continues to Extend Access to Nu.Q® Vet Cancer Test
Rhea-AI Summary
Volition (NYSE: VNRX) announced new laboratory partnerships to expand access to its Nu.Q® Vet Cancer test in the U.S. and Asia. Midwest Veterinary Laboratory will offer the test across all 50 U.S. states beginning February 2026. Bioguard will offer the test via its Animal Health Diagnostic Center, described as the first certified ISO/IEC 17025 animal disease testing laboratory in Taiwan and China. Management highlighted integrating Nu.Q® into annual or senior wellness exams to enable earlier cancer detection in dogs. Volition cited a Total Addressable Market for canine screening of about $100 million for the U.S., Europe and Japan, rising to just under $150 million with China.
Positive
- None.
Negative
- None.
News Market Reaction – VNRX
In the Jan 20 session, VNRX gained 8.42%, reflecting a notable positive market reaction. Argus tracked a peak move of +11.1% during that session. Argus tracked a trough of -9.2% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. Trading volume was very high at 3.7x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 16 | Veterinary symposium | Positive | +0.6% | Sponsored VMX symposium promoting Nu.Q Vet clinical use and conference presence. |
| Jan 08 | Financing agreement | Positive | +24.2% | Secured $2.0M gross proceeds via convertible note and warrants financing. |
| Jan 08 | Feline trial data | Positive | +24.2% | Reported Nu.Q Vet feline data with high specificity and lymphoma detection rates. |
| Dec 17 | Business review | Positive | +10.3% | Outlined 2025 commercial, clinical, IP milestones and initial Nu.Q revenues. |
| Dec 11 | Technology update | Positive | +2.6% | Announced Capture‑Seq liquid biopsy enrichment data and large TAM projection. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news with commercial or clinical progress for Nu.Q has consistently coincided with positive next-day price reactions.
Over the last few months, Volition highlighted multiple milestones around its Nu.Q platform. A Dec 11, 2025 Capture‑Seq™ preprint and a Dec 17, 2025 business review both drew positive reactions. On Jan 8, 2026, breakthrough feline Nu.Q Vet data and a $2.0 million funding agreement also aligned with strong gains. A Jan 16, 2026 veterinary symposium further emphasized Nu.Q Vet usage in practice. Today’s expansion of Nu.Q Vet lab access in the U.S. and Asia continues this commercialization trajectory in companion-animal oncology.
Key Terms
epigenetics medical
iso/iec 17025 regulatory
total addressable market financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Midwest Veterinary Laboratory, a full-service independent reference laboratory in the
U.S. , will be offering the Nu.Q® Vet Cancer test to its customers across all 50 states from February 2026. - Bioguard, a global animal health diagnostics company is now offering the Nu.Q® Vet Cancer Test through it's Animal Health Diagnostic Center, the first certified ISO/IEC 17025 animal disease testing laboratory in
Taiwan andChina .
Dr. Tom Butera, Chief Executive Officer, Volition Veterinary Diagnostics Development LLC commented:
"We are delighted to extend the availability of our groundbreaking Nu.Q® technology in both the
By incorporating the Nu.Q® Canine Cancer Test into annual checkups or regular senior wellness exams, veterinarians can detect cancer earlier[1] and help pet owners make timely, informed decisions about cancer care.
"The market opportunity for Nu.Q® Vet is considerable, with the Total Addressable Market for Canine Screening approximately
- Wilson-Robles, H.M., Bygott, T., Kelly, T.K. et al. Evaluation of plasma nucleosome concentrations in dogs with a variety of common cancers and in healthy dogs. BMC Vet Res 18, 329 (2022). https://doi.org/10.1186/s12917-022-03429-8
- Data on File: Volition TAM
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com, +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of
View original content:https://www.prnewswire.com/news-releases/volition-continues-to-extend-access-to-nuq-vet-cancer-test-302665308.html
SOURCE VolitionRx Limited